Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Cash & Equivalents (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Cash & Equivalents for 14 consecutive years, with $47.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 23.6% year-over-year to $47.7 million, compared with a TTM value of $47.7 million through Dec 2025, down 23.6%, and an annual FY2025 reading of $47.7 million, down 23.6% over the prior year.
  • Cash & Equivalents was $47.7 million for Q4 2025 at Karyopharm Therapeutics, up from $37.7 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $190.5 million in Q4 2021 and bottomed at $762000.0 in Q2 2021.
  • Average Cash & Equivalents over 5 years is $55.4 million, with a median of $50.0 million recorded in 2023.
  • Peak annual rise in Cash & Equivalents hit 10693.7% in 2022, while the deepest fall reached 99.44% in 2022.
  • Year by year, Cash & Equivalents stood at $190.5 million in 2021, then plummeted by 99.44% to $1.1 million in 2022, then soared by 4808.93% to $52.2 million in 2023, then grew by 19.61% to $62.5 million in 2024, then decreased by 23.6% to $47.7 million in 2025.
  • Business Quant data shows Cash & Equivalents for KPTI at $47.7 million in Q4 2025, $37.7 million in Q3 2025, and $34.9 million in Q2 2025.